醋酸奥曲肽注射液联合双歧杆菌三联活菌肠溶胶囊治疗急性胰腺炎患者的疗效及其对氧化应激的影响分析

Efficacy of Octreotide Acetate Injection Combined with Bifidobacterium Triple Viable Bacteria Enteric-coated Capsules in the Treatment of Patients with Acute Pancreatitis and Its Effect on Oxidative Stress

目的探讨醋酸奥曲肽注射液联合双歧杆菌三联活菌肠溶胶囊治疗急性胰腺炎(AP)患者的疗效及对氧化应激的影响。方法方便选取该院2020年1月—2021年10月收治的105例AP患者,以统计学软件随机数模块分成对照组(n=50)和观察组(n=55)。对患者均予以止痛、抑制胃酸分泌、抑制感染等对症治疗,在此基础上对照组使用醋酸奥曲肽注射液治疗,观察组以醋酸奥曲肽联合双歧杆菌三联活菌治疗。对比两组患者症状缓解时间、糖化应激因子水平、炎性因子水平、白细胞水平、血清胰酶水平。结果观察组腹痛缓解时间、腹胀缓解时间分别为(5.39±1.48)、(3.77±1.20)d,均短于对照组的(7.62±1.71)、(5.37±1.52)d,差异有统计学意义(t=7.612、6.014,P<0.05)。治疗前两组患者MDA、ox-LDL、PON-1比较,差异无统计学意义(P>0.05);治疗后观察组MDA、ox-LDL分别为(3.21±0.65)nmol/mL、(64.37±12.42)ng/mL,均低于对照组,PON-1为(116.72±10.76)U/mL,高于对照组,差异有统计学意义(t=4.829、3.167、5.372,P<0.05)。治疗前两组患者CRP、IL-6、IL-10比较,差异无统计学意义(P>0.05);治疗后观察组CRP、IL-6低于对照组,IL-10高于对照组,差异有统计学意义(t=3.543、7.515、3.400,P<0.05)。治疗前两组WBC、AMY、LIPA比较,差异无统计学意义(P>0.05);治疗后观察组WBC、AMY、LIPA指标低于对照组,差异有统计学意义(t=10.596、23.892、11.026,P<0.05)。结论醋酸奥曲肽注射液联合双歧杆菌三联活菌肠溶胶囊治疗可有效促进AP患者腹胀、腹痛的缓解,同时改善患者的氧化应激、炎性因子、白细胞以及血清胰酶指标水平,促进患者的康复。

Objective To investigate the efficacy of octreotide acetate injection combined with Bifidobacterium triple viable enteric-coated capsules in the treatment of patients with acute pancreatitis(AP)and its effect on oxidative stress.Methods Conveniently selected 105 patients with AP treated in the hospital from January 2020 to October 2021 were divided into control group(n=50)and observation group(n=55)according to the random number module of statistical software.All patients were treated with symptomatic treatment such as analgesia,inhibition of gastric acid secretion and inhibition of infection.On this basis,the control group was treated with octreotide acetate injection,and the observation group was treated with octreotide acetate combined with Bifidobacterium triple viable bacteria.The symptom relief time,glycation stress factor level,inflammatory factor level,white blood cell level and serum pancreatin level were compared between the two groups.Results The abdominal pain relief time and abdominal distension relief time in the observation group were(5.39±1.48)d and(3.77±1.20)d,respectively,which were shorter than those in the control group(7.62±1.71)d and(5.37±1.52)d,and the difference was statistically significant(t=7.612,6.014,P<0.05).There was no statistically significant difference in MDA,ox-LDL and PON-1 between the two groups before treatment(P>0.05);after treatment,the levels of MDA and ox-LDL in the observation group were(3.21±0.65)nmol/mL and(64.37±12.42)ng/mL,which were lower than those in the control group,and the levels of PON-1 were(116.72±10.76)U/mL,which were higher than those in the control group,the difference was statistically significant(t=4.829,3.167,5.372,P<0.05).Before treatment,there was no statistically significant difference in CRP,IL-6 and IL-10 between the two groups(P>0.05);after treatment,CRP and IL-6 in the observation group were lower than those in the control group,and IL-10 in the observation group was higher than that in the control group,and the differences were statistically significant(t=3.543,7.515,3.400,P<0.05).There was no statistically significant difference in WBC,AMY and LIPA between the two groups before treatment(P>0.05);after treatment,the indexes of WBC,AMY and LIPA in the observation group were lower than those in the control group,and the difference was statistically significant(t=10.596,23.892,11.026,P<0.05).Conclusion Octreotide acetate injection combined with Bifidobacterium triple viable enteric-coated capsules can effectively promote the relief of abdominal distension and abdominal pain in AP patients.At the same time,the levels of oxidative stress,inflammatory factors,leukocytes and serum pancreatic enzymes of the patients were improved,and the recovery of the patients was promoted.